As the frontrunners in the Covid-19 vaccine race pull ahead Astra touts promising immunogenicity data in older adults.
But the Soloist trial suggests a benefit in heart failure with preserved ejection fraction, which might be good news for Lexicon’s SGLT2 rivals.
The first pivotal results with Moderna’s mRNA-based Covid-19 vaccine look even better than those Biontech/Pfizer released a week ago.
Pfizer is still the only big pharma to have followed Bristol's lead in going all-in on the mechanism.
Survival data with bemarituzumab see the company erase half of the past three years’ losses.
The asthma project tezepelumab shows an effect in both eosinophilic and non-eosinophilic patients.